Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
REDWOOD CITY, Calif., Feb. 03, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 1, 2016, the compensation committee of the company’s board of directors granted 10 new employees options to purchase an aggregate of 17,800 shares of the company’s common stock with a per share exercise price of $18.86, the closing trading price on the grant date, and 8,900 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa™ (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
